Aptinyx (NASDAQ:APTX) Sees Strong Trading Volume

Share on StockTwits

Aptinyx Inc (NASDAQ:APTX) saw unusually-strong trading volume on Monday . Approximately 1,269,936 shares were traded during mid-day trading, an increase of 227% from the previous session’s volume of 388,349 shares.The stock last traded at $3.47 and had previously closed at $3.02.

Several equities analysts recently commented on APTX shares. Cantor Fitzgerald reiterated a “buy” rating on shares of Aptinyx in a research note on Tuesday, April 30th. Zacks Investment Research upgraded Aptinyx from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a research note on Wednesday, March 27th. Cowen reiterated a “buy” rating on shares of Aptinyx in a research note on Monday. Finally, BMO Capital Markets reiterated an “outperform” rating on shares of Aptinyx in a research note on Friday, March 22nd. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $12.95.

The company has a market cap of $105.05 million and a P/E ratio of -1.16.

Aptinyx (NASDAQ:APTX) last posted its earnings results on Tuesday, May 14th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.04). The company had revenue of $0.89 million for the quarter, compared to analysts’ expectations of $1.00 million. Aptinyx had a negative return on equity of 37.53% and a negative net margin of 1,166.40%. As a group, research analysts expect that Aptinyx Inc will post -2.25 earnings per share for the current year.

In related news, Director Henry O. Gosebruch bought 100,000 shares of the company’s stock in a transaction on Wednesday, May 8th. The shares were purchased at an average price of $3.86 per share, for a total transaction of $386,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 8.47% of the company’s stock.

Several large investors have recently bought and sold shares of the business. Great West Life Assurance Co. Can purchased a new stake in shares of Aptinyx during the fourth quarter worth $40,000. Partner Investment Management L.P. lifted its position in shares of Aptinyx by 4.6% during the fourth quarter. Partner Investment Management L.P. now owns 58,840 shares of the company’s stock worth $973,000 after acquiring an additional 2,570 shares in the last quarter. Barclays PLC lifted its position in shares of Aptinyx by 87.1% during the fourth quarter. Barclays PLC now owns 9,323 shares of the company’s stock worth $154,000 after acquiring an additional 4,340 shares in the last quarter. Metropolitan Life Insurance Co. NY lifted its position in shares of Aptinyx by 356.6% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 7,237 shares of the company’s stock worth $120,000 after acquiring an additional 5,652 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in shares of Aptinyx by 71.0% during the fourth quarter. Rhumbline Advisers now owns 16,944 shares of the company’s stock worth $280,000 after acquiring an additional 7,033 shares in the last quarter. Hedge funds and other institutional investors own 58.37% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Aptinyx (NASDAQ:APTX) Sees Strong Trading Volume” was published by Highlight Press and is the property of of Highlight Press. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://highlightpress.com/2019/06/13/aptinyx-nasdaqaptx-sees-strong-trading-volume.html.

Aptinyx Company Profile (NASDAQ:APTX)

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.

Further Reading: Support Level

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.